Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30263662 | 0.81 | KDM4E (0.55) | KDM4ELMNAHTTALDH1A1MAPT | |
| SCHEMBL26789945 | 0.81 | KDM4E (0.55) | KDM4ELMNAHTTALDH1A1MAPT | |
| SCHEMBL23767660 | 0.77 | LMNA (0.36) | LMNA | |
| SCHEMBL18544785 | 0.74 | HTT (0.55) | KDM4ELMNAMAPK1HTTALDH1A1 | |
| SCHEMBL25931805 | 0.71 | LMNA (0.38) | KDM4ELMNAMAPK1HTTALDH1A1 | |
| SCHEMBL19055889 | 0.69 | PDE2A (0.41) | — | |
| SCHEMBL17561688 | 0.69 | KDM4E (0.55) | KDM4ELMNAHTTALDH1A1MAPT | |
| SCHEMBL30263530 | 0.68 | DYRK1A (0.53) | KDM4ELMNAHTTALDH1A1MAPT | |
| SCHEMBL4821253 | 0.68 | DYRK1A (0.53) | KDM4ELMNAHTTALDH1A1MAPT | |
| SCHEMBL24320223 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | KDM4E 687/4885LMNA 896/4885MAPK1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.